BioNTech is clearly impressed with what it has seen with partner Biotheus' bispecific antibody for cancer, opting to buy the company outright to get full control of the drug. The two companies ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

With the completion of the acquisition, BioNTech is set to obtain complete rights to the pipeline products and bispecific antibody-drug conjugate technology of Biotheus, expanding its presence in ...

Several pharma CEOs met with Chinese President Xi Jinping in Beijing. President Donald Trump's reciprocal tariffs have mostly ...

“Building on Novimmune’s long experience in antibody discovery and development, Light Chain Bioscience now focuses on leveraging the unique features of its bispecific antibody format”, said ...

Gilead Sciences has made yet another rush into the oncology category, licensing a bispecific antibody from MacroGenics in development as a treatment for CD123-positive blood cancers, including ...

During that time, explained Seil Jang, antibody engineering team lead at Y-Biologics, the drawbacks of the mutation-based engineering system typically used to create bispecific antibodies became ...

Bispecific antibodies first reached patients ... index and a superior safety profile compared to other targeted antibody therapies, such as T cell engagers (TCEs) and antibody drug conjugates ...

ImmunoPrecise Antibodies has secured a collaboration with an undisclosed “leading biotech” to discover new antibody-drug conjugates and bispecific antibodies to treat cancer. The agreement wil ...

The first-in-class and so far best-in-class PD-1xVEGF bispecific antibody ivonescimab has set the bar for competitors in the pipeline for a superior clinical profile compared with anti-PD-1 ...